Gedatolisib plus fulvestrant, with and without palbociclib, versus fulvestrant in patients with HR+/ HER2-/PIK3CA wild-type advanced breast cancer: first results from VIKTORIA-1
NCODA Oncology and Hematology Meeting Abstracts · 07.04.2026
DOI: 10.67209/hgsl3836 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 07.04.2026. Verfasst von Sara Hurvitz und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: Celcuity.
Abstract (Originalsprache)
Background
The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR [PAM]) pathway drives breast cancer growth and resistance to endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Combining PAM inhibition with ET + CDK4/6i after progression may restore sensitivity. However, most approved agents that target single components of this pathway require direct PI3K-pathway alteration for clinical benefit. Gedatolisib, a potent pan-class I PI3K and mammalian target of rapamycin complex 1/2 (mTORC1/2) inhibitor, blocks PAM signaling regardless of PIK3CA status. The phase 3 VIKTORIA-1 trial evaluates gedatolisib-based therapy in patients with HR+/HER2- advanced breast cancer (ABC) that progressed on or after standard therapy. Patients are enrolled to Study 1 or Study 2 based on PIK3CA status (wild-type [WT] versus [vs] mutated). Here, we encore Study 1 top-line safety and efficacy data.
Objectives
Analyze top-line safety and efficacy data from the VIKTORIA-1 trial.
Methods
Eligible patients with HR+/HER2- ABC that progressed on/after CDK4/6i + nonsteroidal aromatase inhibitor (AI) and radiologically evaluable disease (per RECIST v1.1) with no prior chemotherapy for ABC and no prior PAM inhibitor therapy. Study 1 patients were randomized to gedatolisib plus palbociclib plus fulvestrant (triplet), gedatolisib plus fulvestrant (doublet), or fulvestrant alone, stratified by visceral metastases, time to radiologic disease progression on immediate prior therapy, and geographic region. Patients in the fulvestrant arm could cross over to gedatolisib treatment upon progression. Co-primary endpoints were progression-free survival (PFS), assessed by blinded independent central review (BICR), for the triplet vs fulvestrant and the doublet vs fulvestrant.
Results
At data cut-off (May 30, 2025), 392 pts with PIK3CA WT disease had been randomized. Median study follow-up was 10.1 months. The trial met its primary endpoints, with median PFS (mPFS) for the triplet vs fulvestrant of 9.3 vs 2.0 months (HR, 0.24; 95% CI, 0.17-0.35; P
Förderung
- Celcuity
Zitieren
APA
Hurvitz, S., Layman, R., Curigliano, G., Cristofanilli, M., Wesolowski, R., Han, H., Giordano, A., Gorbatchevsky, I., & Pistilli, B. (2026). Gedatolisib plus fulvestrant, with and without palbociclib, versus fulvestrant in patients with HR+/ HER2-/PIK3CA wild-type advanced breast cancer: first results from VIKTORIA-1. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/hgsl3836
Vancouver
Hurvitz S, Layman R, Curigliano G, Cristofanilli M, Wesolowski R, Han H, et al. Gedatolisib plus fulvestrant, with and without palbociclib, versus fulvestrant in patients with HR+/ HER2-/PIK3CA wild-type advanced breast cancer: first results from VIKTORIA-1. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/hgsl3836
BibTeX
@article{Hurvitz2026,
author = {Hurvitz, Sara and Layman, Rachel and Curigliano, Giuseppe and Cristofanilli, Massimo and Wesolowski, Robert and Han, Hyo and Giordano, Antonio and Gorbatchevsky, Igor and Pistilli, Barbara},
title = {Gedatolisib plus fulvestrant, with and without palbociclib, versus fulvestrant in patients with HR+/ HER2-/PIK3CA wild-type advanced breast cancer: first results from VIKTORIA-1},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/hgsl3836}
}
EUVIMED